Trimethobenzamidum
Trimethobenzamidum Uses, Dosage, Side Effects, Food Interaction and all others data.
Trimethobenzamidum is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against emesis induced by intragastric copper sulfate.
Trade Name | Trimethobenzamidum |
Availability | Prescription only |
Generic | Trimethobenzamide |
Trimethobenzamide Other Names | Trimethobenzamide, Trimethobenzamidum, Trimetobenzamida |
Related Drugs | hydroxyzine, lorazepam, ondansetron, Zofran, meclizine, promethazine |
Type | |
Formula | C21H28N2O5 |
Weight | Average: 388.4574 Monoisotopic: 388.199822016 |
Groups | Approved, Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
Trimethobenzamidum is an antiemetic used to treat postoperative nausea and vomiting and nausea associated with gastroenteritis.
For the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.
Trimethobenzamidum is also used to associated treatment for these conditions: Nausea, Nausea and vomiting
How Trimethobenzamidum works
The mechanism of action of trimethobenzamide as determined in animals is obscure, but may involve the chemoreceptor trigger zone (CTZ), an area in the medulla oblongata through which emetic impulses are conveyed to the vomiting center; direct impulses to the vomiting center apparently are not similarly inhibited.
Toxicity
Oral LD50 in mice is 1600 mg/kg.
Food Interaction
- Avoid alcohol. Ingestion of alcohol may increase the CNS depressant effects of trimethobenzamide causing drowsiness.
[Moderate] GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.
Use in combination may result in additive central nervous system depression and
MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.
Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.
Trimethobenzamidum Drug Interaction
Moderate: diphenhydramine, duloxetine, meperidine, pregabalin, gabapentin, quetiapine, metaxalone, alprazolam, sertralineUnknown: calcium / vitamin d, celecoxib, sulfamethoxazole / trimethoprim, ubiquinone, atorvastatin, polyethylene glycol 3350, esomeprazole, montelukast, cyanocobalamin, cholecalciferol, ondansetron
Trimethobenzamidum Disease Interaction
Major: Reye's syndromeModerate: parkinsonism, renal impairment
Elimination Route
The relative bioavailability of the capsule formulation compared to the solution is 100%.
Half Life
The mean elimination half-life of trimethobenzamide is 7 to 9 hours.
Elimination Route
Between 30 – 50% of a single dose in humans is excreted unchanged in the urine within 48–72 hours.
Innovators Monograph
You find simplified version here Trimethobenzamidum